Trial Profile
Extension Study of Protocol ENB-006-09 Evaluating the Long-term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 18 Mar 2019 Pooled results from this and five other studies were presented at the 101st Annual Meeting of the Endocrine Society.
- 04 Apr 2016 Status changed from active, no longer recruiting to completed, according to the results presented at The 98th Annual Meeting of the Endocrine Society
- 04 Apr 2016 Results from this trial were presented at the the Endocrine Society's 98th Annual Meeting and Expo (ENDO), according to an Alexion Pharmaceuticals media release.